Bcl-2转录抑制因子1在结肠癌中的表达及其临床意义

Expression and clinical significance of Bcl-2 transcriptional repressor 1 in colon cancer

摘要

目的：探究Bcl-2转录抑制因子1(Bcl-2 inhibitor of transcription 1，BIT1)在结肠癌中的表达及其对结肠癌细胞生物学行为的影响。方法：采用生物信息学分析BIT1在结肠癌组织中的表达与临床病理参数及预后的关联。qRT-PCR、Western blot验证BIT1在结肠癌细胞株中的表达水平；利用质粒转染敲低结肠癌细胞中BIT1的表达，通过CCK-8、EdU、细胞划痕、Transwell实验和流式细胞术观察结肠癌细胞增殖、迁移、侵袭及细胞周期的变化。结果：基于数据库分析及qRT-PCR、Western blot检测发现BIT1在结肠癌中表达上调（P＜0.05），且与患者预后生存期呈负相关（P＜0.05）。敲低HCT116细胞株的BIT1表达，其增殖、迁移及侵袭能力受到显著抑制（P＜0.05），细胞周期停滞于G ₁期（P＜0.05）。结论：BIT1在结肠癌中高表达，与结肠癌细胞的恶性生物学行为密切相关；BIT1有望成为结肠癌早期诊断的生物学标志物和治疗靶点。

Abstract

Objective: Explore the expression of Bcl-2 inhibitor of transcription 1(BIT1) in colon cancer and its effect on the biological behavior of colon cancer cells. Methods: Using bioinformatics to analyze the association of BIT1 expression in colon cancer tissues with clinicopathological parameters and prognosis. qRT-PCR and Western blot were used to validate the expression levels of BIT1 in colon cancer cell lines. Plasmid transfection was employed to knock down the expression of BIT1 in colon cancer cells, and CCK-8, EdU, cell scratch, Transwell assays, and flow cytometry were conducted to explore the effects of BIT1 on the proliferation, migration, invasion, and cell cycle changes of colon cancer cells. Results: Based on database analysis and qRT-PCR and Western blot detection, BIT1 was found to be upregulated in colon cancer(P＜0.05) and negatively correlated with patients' overall survival(P＜0.05). Silencing BIT1 expression in HCT116 cells significantly inhibited their proliferation, migration, and invasion abilities(P＜0.05), and caused cell cycle arrest in the G1 phase(P＜0.05). Conclusion: BIT1 is highly expressed in colon cancer, which is closely related to the malignant biological behaviors of colon cancer cells, and is expected to be a biological marker for early diagnosis and a therapeutic target of colon cancer.

关键词

结肠肿瘤 / Bcl-2转录抑制因子1 / 生物信息学

Key words

Colon neoplasms / Bcl-2 transcriptional repressor 1 / Bioinformatics

参考文献

[1] Sung H , Ferlay J , Siegel RL , et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

[2] Xi Y , Xu P . Global colorectal cancer burden in 2020 and projections to 2040[J]. Transl Oncol, 2021, 14(10): 101174. DOI: 10.1016/j.tranon.2021.101174.

[3] Kanth P , Inadomi JM . Screening and prevention of colorectal cancer[J]. BMJ, 2021, 374: n1855. DOI: 10.1136/bmj.n1855.

[4] 滕文豪， 郝立亮， 李光， 等 . MRPL37在结直肠癌中的表达及与临床病理的相关性[J]. 中国现代普通外科进展， 2024， 27（7）： 517-521. DOI: 10.3969/j.issn.1009—9905.2024.07.003.

[5] Stupack DG , Cheresh DA . A Bit—role for integrins in apoptosis[J]. Nat Cell Biol, 2004, 6(5): 388-389. DOI: 10.1038/ncb0504—388.

[6] De Pereda JM , Waas WF , Jan Y , et al. Crystal structure of a human peptidyl—tRNA hydrolase reveals a new fold and suggests basis for a bifunctional activity[J]. J Biol Chem, 2004, 279(9): 8111-8115. DOI: 10.1074/jbc.M311449200.

[7] Corpuz AD , Ramos JW , Matter ML . PTRH2: an adhesion regulated molecular switch at the nexus of life, death, and differentiation[J]. Cell Death Discov, 2020, 6(1): 124. DOI: 10.1038/s41420—020—00357—0.

[8] 刘佳玲， 黄林生， 叶星宇， 等 . 失巢凋亡效应分子bcl—2转录抑制因子1的研究进展[J]. 肿瘤研究与临床， 2020， 32（2）： 4. DOI: 10.3760/cma.j.issn.1006—9801.2020.02.015.

[9] Dekker E , Tanis PJ , Vleugels JLA , et al. Colorectal cancer[J]. Lancet, 2019, 394(10207): 1467-1480. DOI: 10.1016/S0140—6736(19)32319—0.

[10] Vodenkova S , Buchler T , Cervena K , et al. 5—fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future[J]. Pharmacol Ther, 2020, 206: 107447. DOI: 10.1016/j.pharmthera.2019.107447.

[11] Taddei ML , Giannoni E , Fiaschi T , et al. Anoikis: an emerging hallmark in health and diseases[J]. J Pathol, 2012, 226(2): 380-393. DOI: 10.1002/path.3000.

[12] Raeisi M , Zehtabi M , Velaei K , et al. Anoikis in cancer: The role of lipid signaling[J]. Cell Biol Int, 2022, 46(11): 1717-1728. DOI: 10.1002/cbin.11896.

[13] Wang J , Luo Z , Lin L , et al. Anoikis—Associated Lung Cancer Metastasis: Mechanisms and Therapies[J]. Cancers(Basel), 2022, 14(19): 4791. DOI: 10.3390/cancers14194791.

[14] Dai Y , Zhang X , Ou Y , et al. Anoikis resistance——protagonists of breast cancer cells survive and metastasize after ECM detachment[J]. Cell Commun Signal, 2023, 21(1): 190. DOI: 10.1186/s12964—023—01183—4.

[15] 张三柯 . Bit—1通过IL—6/IL—6R—STAT3途径调控口腔鳞状细胞癌的迁移、侵袭和凋亡能力的研究[D]. 郑州大学， 2019.

[16] Fan T , Chen J , Zhang L , et al. Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK—paxillin pathway[J]. Mol Cancer, 2016, 15: 23. DOI: 10.1186/s12943—016—0507—5.

[17] 罗金玉， 王法， 郭昆峰， 等 . Bit—1蛋白在膀胱癌中的表达及临床意义[J]. 解剖科学进展， 2017， 23（6）： 587—589， 592. DOI: 10.16695/j.cnki.1006—2947.2017.06.010.

[18] 王进 . PTRH2通过激活TNF通路促进炎症来促进肾透明细胞癌增殖和迁移的机制研究[D]. 大连医科大学， 2024. DOI: 10.26994/d.cnki.gdlyu.2024.000830.

[19] Yao X , Jennings S , Ireland SK , et al. The anoikis effector Bit1 displays tumor suppressive function in lung cancer cells[J]. PLoS One, 2014, 9(7): e101564. DOI: 10.1371/journal.pone.0101564.

[20] Wang Z , Yin M , Wang R , et al. Bit1 Silencing Enhances the Proliferation, Migration, and Invasion of Glioma Cells Through Activation of the IL—6/STAT3 Pathway[J]. Onco Targets Ther, 2020, 13: 2469-2481. DOI: 10.2147/OTT.S240081.

[21] Manfioletti G , Fedele M . Epithelial—Mesenchymal Transition(EMT) 2021[J]. Int J Mol Sci, 2022, 23(10): 5848. DOI: 10.3390/ijms23105848.

[22] Hashemi M , Arani HZ , Orouei S , et al. EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions[J]. Biomed Pharmacother, 2022, 155: 113774. DOI: 10.1016/j.biopha.2022.113774.

[23] 黄帅 . Bit1蛋白对胰腺癌恶性表型调控作用及机制研究[D]. 北京协和医学院， 2016.

[24] Huang L , Xu M , Zhao X , et al. Bit1 promotes the progression of gastric cancer by facilitating epithelial—mesenchymal transition and alleviating apoptosis[J]. Med Oncol, 2025, 42(7): 231. DOI: 10.1007/s12032—025—02781—7.

[25] 刘佳玲 . 西妥昔单抗通过调控EGFR/integrin β1/Bit1轴抑制EMT进程阻碍Bit1高表达肝癌进展[D]. 湖北医药学院， 2020. DOI: 10.27913/d.cnki.ghyby.2020.000052.

基金资助

河北省医学科学研究课题计划资助项目(20200210)

河北省医学科学研究课题计划资助项目(20260711)